The Latest Findings of the Comprehensive Management of Intrahepatic Hepatocellular Carcinoma through the Combined Use of Lenvatinib and Locoregional Therapies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 1 May 2025 | Viewed by 228
Special Issue Editors
Interests: diagnosis and treatment of hepatocellular carcinoma; prediction of tumor malignant; potential and therapeutic application; radiofrequency ablation (RFA); transcatheter arterial chemoembolization (TACE); molecular target therapy
Interests: hepatocellular carcinoma; molecular targeted agents; transcatheter arterial chemoembolization; radiofrequency ablation; multityrosine kinase inhibitor
Special Issue Information
Dear Colleagues,
What are the goals for the long-term survival of patients with hepatocellular carcinoma (HCC)? The control of extrahepatic metastases, or the control of intrahepatic lesions? The current answer is the control of intrahepatic lesions.
The importance of intrahepatic tumor control for long-term survival in patients with extrahepatic tumor spread has also been reported.
For the control of intrahepatic lesions in unresectable HCC, radiofrequency ablation, transarterial chemoembolization (TACE), transarterial chemo infusion therapy (TAI), radiation therapy (stereotactic radiotherapy, intensity modulated radiation therapy, and particle beam therapy), and systemic therapies are our treatment options. On the other hand, the combination of lenvatinib and locoregional therapy has also come into the limelight. Since the introduction of lenvatinib, encouraging results have been reported on its highly synergistic effect with TACE based on anti-tumor vessel effects and high treatment efficacy in patients with oncologically aggressive HCC. The effect on tumor blood vessels has been supported by basic and clinical research, and the synergistic effects of radiation therapy by improving hypoxia are also expected. Moreover, a high conversion rate from unresectable to resectable has been reported.
In this Special Issue, it is hoped that the drug characteristics of lenvatinib, its synergistic effects with various therapies, and its role in the era of immunotherapy will be clarified.
Dr. Yusuke Kawamura
Dr. Tomokazu Kawaoka
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lenvatinib
- hepatocellular carcinoma
- transarterial chemoembolization
- transarterial chemo infusion therapy
- radiation therapy
- radiofrequency ablation
- systemic therapy
- surgery
- surgical resection
- locoregional therapy
